Management of malignant ovarian immature teratoma. Role of adriamycin.
Sixteen consecutive patients with pure ovarian immature teratoma have been treated at The Norwegian Radium Hospital between 1975 and 1987. The median age was 22 years. Thirteen patients had International Federation of Gynecology and Obstetrics (FIGO) Stage I disease and three had Stage III disease. None of the patients with Stage I disease had bilateral disease. In nine patients at least one ovary was conserved. Four cases were Grade 1, seven cases Grade 2, and five cases Grade 3. Adjuvant treatment consisted mainly of Adriamycin (Adria Laboratories, Columbus, OH). The chemotherapy regimen appeared to be highly effective because all patients are alive without evidence of disease (median follow-up, 85 months). No severe toxicity was observed. In patients without residual tumor after primary surgery, the authors prefer the adjuvant treatment with Adriamycin because this treatment has a lower toxicity and is as effective as combination chemotherapy (vincristine, dactinomycin, and cyclophosphamide or cisplatin, vinblastine and bleomycin). Some comments on initial surgery and second-look surgery are also given.
Department of Gynecologic Oncology, Norwegian Radium Hospital, Oslo.
I B
IB
Vergote
V M
VM
Abeler
K E
KE
Kjørstad
C
C
Tropé
D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D009664:Norway; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D015996:Survival Rate; D013724:Teratoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery
D004317:Doxorubicin